Cio Bulletin
| Company | Management | Description |
|---|---|---|
| PBS Biotech | Brian Lee Founder & CEO |
PBS Biotech aims to be the leading provider of innovative, single-use bioreactor systems specifically designed to address the unique challenges of cultivating shear sensitive cell types for cell therapy development. |
| Quercis Pharma | Thomas Lines Director & CEO |
Quercis Pharma, headquartered in Zug, Switzerland, is a privately owned biopharmaceutical company at the forefront of precision medicine and therapeutic innovation. The company strategically focuses on an advanced development pipeline, with a primary emphasis on late-stage clinical studies targeting the prevention of Venous Thromboembolism (VTE) in cancer patients and addressing the specific challenges associated with sickle cell disease. |
| Celmatix | Dr. Piraye Yurttas Beim, PhD Founder & CEO |
Celmatix is a preclinical-stage biotech transforming women’s lives through better ovarian health. |
| Cellares | Fabian Gerlinghaus Co-Founder & CEO |
Cellares is the first Integrated Development and Manufacturing Organization (IDMO) and takes an Industry 4.0 approach to mass manufacturing the living drugs of the 21st century. The company is both developing and operating integrated technologies for cell therapy manufacturing to accelerate access to life-saving cell therapies. |
| Volastra Therapeutics | Dr. Charles Hugh-Jones, CEO |
Volastra Therapeutics is a New York-based drug discovery and therapeutics company pioneering novel approaches to treating cancer by exploiting chromosomal instability (CIN), cancer’s most targetable vulnerability. |
.webp)
 consultants ltd.jpg)
